NZ589299A - 2-[Heteroaryl]alkyl-1,2,3,4-tetrahydro-quinoline derivatives for the treatment of cancer etc. - Google Patents
2-[Heteroaryl]alkyl-1,2,3,4-tetrahydro-quinoline derivatives for the treatment of cancer etc.Info
- Publication number
- NZ589299A NZ589299A NZ589299A NZ58929909A NZ589299A NZ 589299 A NZ589299 A NZ 589299A NZ 589299 A NZ589299 A NZ 589299A NZ 58929909 A NZ58929909 A NZ 58929909A NZ 589299 A NZ589299 A NZ 589299A
- Authority
- NZ
- New Zealand
- Prior art keywords
- group
- alkyl
- independently selected
- alkynyl
- alkenyl
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000000304 alkynyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- GVGKWFMHKMRTID-UHFFFAOYSA-N 2-[2-(2,5-dimethyl-1-phenylpyrrol-3-yl)ethenyl]-n,n,1-trimethyl-3,4-dihydro-2h-quinolin-6-amine Chemical compound C1CC2=CC(N(C)C)=CC=C2N(C)C1C=CC(=C1C)C=C(C)N1C1=CC=CC=C1 GVGKWFMHKMRTID-UHFFFAOYSA-N 0.000 abstract 1
- VPYRGWCZTSWJQU-UHFFFAOYSA-N 2-[2-(2,5-dimethyl-1-phenylpyrrol-3-yl)ethyl]-n,n,1-trimethyl-3,4-dihydro-2h-quinolin-6-amine Chemical compound C1CC2=CC(N(C)C)=CC=C2N(C)C1CCC(=C1C)C=C(C)N1C1=CC=CC=C1 VPYRGWCZTSWJQU-UHFFFAOYSA-N 0.000 abstract 1
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010020112 Hirsutism Diseases 0.000 abstract 1
- 206010066364 Hypersexuality Diseases 0.000 abstract 1
- 206010020864 Hypertrichosis Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010033888 Paraphilia Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 201000010272 acanthosis nigricans Diseases 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- -1 alkyl-OH Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 231100000360 alopecia Toxicity 0.000 abstract 1
- 230000002280 anti-androgenic effect Effects 0.000 abstract 1
- 239000000051 antiandrogen Substances 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 208000006155 precocious puberty Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4755908P | 2008-04-24 | 2008-04-24 | |
| PCT/US2009/041715 WO2009132307A1 (en) | 2008-04-24 | 2009-04-24 | Small-molecule inhibitors of the androgen receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ589299A true NZ589299A (en) | 2013-01-25 |
Family
ID=41217163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ589299A NZ589299A (en) | 2008-04-24 | 2009-04-24 | 2-[Heteroaryl]alkyl-1,2,3,4-tetrahydro-quinoline derivatives for the treatment of cancer etc. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8354538B2 (enExample) |
| EP (1) | EP2276345A4 (enExample) |
| JP (1) | JP5599385B2 (enExample) |
| KR (1) | KR101640512B1 (enExample) |
| AU (1) | AU2009240417B2 (enExample) |
| CA (1) | CA2722340A1 (enExample) |
| NZ (1) | NZ589299A (enExample) |
| WO (1) | WO2009132307A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2496135B (en) * | 2011-11-01 | 2015-03-18 | Valirx Plc | Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis |
| EP2959013A2 (en) * | 2013-02-25 | 2015-12-30 | Novartis AG | Novel androgen receptor mutation |
| GB2513615A (en) | 2013-05-01 | 2014-11-05 | Cancer Rec Tech Ltd | Medical use |
| EP3350167A4 (en) | 2015-09-04 | 2019-04-03 | City of Hope | Androgen receptor Antagonist |
| WO2019126739A1 (en) | 2017-12-21 | 2019-06-27 | Shepherd Therapeutics, Inc. | Pyrvinium pamoate anti-cancer therapies |
| WO2019152731A1 (en) * | 2018-01-31 | 2019-08-08 | Alpine Androsciences, Inc. | Androgen receptor antagonists |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1166538A (en) * | 1967-06-10 | 1969-10-08 | Pfizer Ltd | Substituted Tetrahydroquinolines |
| DE2421382A1 (de) * | 1974-05-03 | 1975-11-20 | Council Scient Ind Res | 1-substituierte 4-(beta-2-chinolylaethyl)- piperazine und deren 1,2,3,4-tetrahydrochinolinanaloge |
| US3983121A (en) * | 1974-07-01 | 1976-09-28 | Council Of Scientific And Industrial Research | 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof |
| US5840500A (en) * | 1996-07-11 | 1998-11-24 | Trega Biosciences, Inc. | Quinoline derivatives and quinoline combinatorial libraries |
| AU7558900A (en) * | 1999-10-14 | 2001-04-23 | Kaken Pharmaceutical Co., Ltd. | Tetrahydroquinoline derivatives |
| WO2002022585A1 (en) * | 2000-09-14 | 2002-03-21 | Kaken Pharmaceutical Co., Ltd. | Tetrahydroquinoline compounds |
| ITMI20012060A1 (it) * | 2001-10-05 | 2003-04-05 | Recordati Chem Pharm | Nuovi eterocilcli n-acilati |
| CN1506359A (zh) | 2002-12-05 | 2004-06-23 | �й�ҽѧ��ѧԺҩ���о��� | 新的香豆素酰胺衍生物及其制法和其药物组合物与用途 |
| US8519158B2 (en) * | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| CA2576988A1 (en) * | 2004-08-25 | 2006-03-09 | Merck & Co., Inc. | Androgen receptor modulators |
| US20080281105A1 (en) * | 2005-01-18 | 2008-11-13 | Immusol Incorporated | Novel Quinolinium Salts and Derivatives |
| WO2007117466A2 (en) | 2006-03-31 | 2007-10-18 | Massachusetts Institute Of Technology | Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors |
| WO2008128100A1 (en) | 2007-04-13 | 2008-10-23 | The Regents Of The University Of California | Small-molecule inhibitors of the androgen receptor |
-
2009
- 2009-04-24 JP JP2011506486A patent/JP5599385B2/ja not_active Expired - Fee Related
- 2009-04-24 AU AU2009240417A patent/AU2009240417B2/en not_active Ceased
- 2009-04-24 EP EP09735196A patent/EP2276345A4/en not_active Withdrawn
- 2009-04-24 WO PCT/US2009/041715 patent/WO2009132307A1/en not_active Ceased
- 2009-04-24 KR KR1020107026231A patent/KR101640512B1/ko not_active Expired - Fee Related
- 2009-04-24 CA CA2722340A patent/CA2722340A1/en not_active Abandoned
- 2009-04-24 NZ NZ589299A patent/NZ589299A/xx not_active IP Right Cessation
- 2009-04-24 US US12/989,389 patent/US8354538B2/en not_active Expired - Fee Related
-
2012
- 2012-12-06 US US13/706,647 patent/US8580773B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP5599385B2 (ja) | 2014-10-01 |
| KR20110002872A (ko) | 2011-01-10 |
| WO2009132307A1 (en) | 2009-10-29 |
| KR101640512B1 (ko) | 2016-07-18 |
| EP2276345A1 (en) | 2011-01-26 |
| JP2011518843A (ja) | 2011-06-30 |
| US20130096095A1 (en) | 2013-04-18 |
| CA2722340A1 (en) | 2009-10-29 |
| US20110224253A1 (en) | 2011-09-15 |
| AU2009240417B2 (en) | 2014-06-26 |
| US8580773B2 (en) | 2013-11-12 |
| AU2009240417A1 (en) | 2009-10-29 |
| EP2276345A4 (en) | 2012-06-06 |
| US8354538B2 (en) | 2013-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2498798C2 (ru) | Ингибиторы карбоангидразы iх | |
| DE60304059D1 (de) | 3-(2-hydroxy-phenyl)-1h-pyrazol-4-carbonsäureamid derivate als hsp90 inhibitoren zur behandlung von krebs | |
| BG105666A (en) | Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method for forming the complex | |
| CO5611147A2 (es) | Derivados de nicotinamida utiles como inhibidores p38 | |
| ATE463483T1 (de) | 6-substituierte isochinolinderivate als rock-1- inhibitoren | |
| IN2012DN00573A (enExample) | ||
| TW200728292A (en) | Pyrazinecarboxamide derivatives and plant disease controlling agents containing the same | |
| NZ587051A (en) | Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase) | |
| MY161631A (en) | Herbicidal pyrimidone derivatives | |
| MY152008A (en) | Pyrrole compounds | |
| AR079495A1 (es) | Derivados de fenilimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| MX2013004407A (es) | Derivado de piridina y agente medicinal. | |
| PE20061305A1 (es) | Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas | |
| EA201170098A1 (ru) | Замещенные производные алкилпиримидин-4-она | |
| IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| NZ597638A (en) | 5-fluoro-2-oxopyrimidine- 1(2h)-carboxylate derivatives | |
| DE60123674D1 (de) | Perylenpigmentzusammensetzungen | |
| WO2008140066A3 (en) | Pyridone derivatives as p38a mapk inhibitors | |
| DE60027700D1 (de) | Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden | |
| MY160882A (en) | Biocidal composition and method | |
| MX2012007223A (es) | Carboxamidas fungicidas 2-(ariloxi biciclicas). | |
| ATE417841T1 (de) | Furanderivate als ep4-rezeptorantagonisten | |
| IN2012DN02871A (enExample) | ||
| NO20071253L (no) | Fremgangsmate for syntese av C-2, C-3 substituerte N-alkylerte indoler anvendbare som CPLA2-inhibitorer. | |
| WO2005036961A3 (en) | N-substituted azacycles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 24 APR 2016 BY COMPUTER PACKAGES INC Effective date: 20130709 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 APR 2017 BY COMPUTER PACKAGES INC Effective date: 20160331 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 APR 2018 BY COMPUTER PACKAGES INC Effective date: 20170331 |
|
| LAPS | Patent lapsed |